Compare Stocks

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Therapeutics	$1.35 -12.3%	$1.37	$0.59 ▼ $2.31	$169.16M	1.2	1.39 million shs	4.06 million shs
OBLN Obalon Therapeutics	$0.16	$4.22	$0.66 ▼ $10.77	$1.64M	-1.23	7.68 million shs	243,173 shs
TMDI Titan Medical	$0.14 -26.3%	$0.23	$0.13 ▼ $1.20	$15.67M	2.36	4.83 million shs	7.71 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Therapeutics	-9.94%	-16.30%	+19.38%	+87.10%	+108.11%
OBLN Obalon Therapeutics	-1.82%	-7.00%	-0.62%	-33.81%	-94.84%
TMDI Titan Medical	0.00%	0.00%	0.00%	0.00%	0.00%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATOS Atossa Therapeutics	1.3057 of 5 stars	3.5	1.0	0.0	0.0	3.0	1.7	0.0
OBLN Obalon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TMDI Titan Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Therapeutics	3.00	Buy	$4.50	233.33% Upside
OBLN Obalon Therapeutics	N/A	N/A	N/A	N/A
TMDI Titan Medical	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TMDI, ATOS, and OBLN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/16/2024	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
4/2/2024	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
2/12/2024	ATOS Atossa Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$4.00

(Data available from 4/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
OBLN Obalon Therapeutics	$1.59M	1.03	N/A	N/A	$0.60 per share	0.27
TMDI Titan Medical	$20.09M	0.78	N/A	N/A	$0.32 per share	0.44

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Therapeutics	-$30.09M	-$0.24	N/A	N/A	N/A	N/A	-31.01%	-29.77%	5/20/2024 (Estimated)
OBLN Obalon Therapeutics	-$12.33M	N/A	N/A	∞	N/A	-776.76%	-161.38%	-83.58%	N/A
TMDI Titan Medical	-$14.86M	-$0.19	N/A	∞	N/A	N/A	-167.03%	-112.15%	N/A

Latest TMDI, ATOS, and OBLN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/1/2024	Q4 2023	ATOS Atossa Therapeutics	N/A	-$0.06	-$0.06	-$0.06	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Therapeutics	N/A	N/A	N/A	N/A	N/A
OBLN Obalon Therapeutics	N/A	N/A	N/A	N/A	N/A
TMDI Titan Medical	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Therapeutics	N/A	17.61	17.61
OBLN Obalon Therapeutics	N/A	1.86	1.86
TMDI Titan Medical	N/A	1.41	1.41

Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Therapeutics	12.74%
OBLN Obalon Therapeutics	18.64%
TMDI Titan Medical	3.55%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Therapeutics	7.80%
OBLN Obalon Therapeutics	8.10%
TMDI Titan Medical	0.02%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Therapeutics	11	125.30 million	115.53 million	Optionable
OBLN Obalon Therapeutics	2	10.02 million	N/A	Not Optionable
TMDI Titan Medical	49	111.95 million	111.93 million	Not Optionable

TMDI, ATOS, and OBLN Headlines

Source	Headline
	Titan Medical Inc.: Titan Medical Reports Fiscal Year 2023 Results finanznachrichten.de - April 1 at 8:49 AM
	Titan Medical signs deal to merge with Conavi Medical msn.com - March 21 at 4:35 AM
	Titan Medical Inc TMDIF morningstar.com - February 27 at 7:19 PM
	Perifery appoints Titan Data Solutions as authorised distributor advanced-television.com - February 13 at 8:31 AM
	Titan Medical Inc (TMD) investing.com - February 13 at 1:56 AM
	Vantage Titan 3T MRI Scanner from Toshiba news-medical.net - January 11 at 8:10 AM
	Attack on Titan: Hajime Isayama Will Create New Titan Story in 2024 comicbook.com - October 3 at 1:41 AM
	Five dead on Titan sub were 'true explorers' - OceanGate bbc.com - September 28 at 10:21 PM
	TMDIF Titan Medical Inc. seekingalpha.com - August 1 at 7:27 PM
	False claim Titan passenger was the vice chairman of the World Economic Forum \| Fact check usatoday.com - July 25 at 1:09 PM
	New details emerge about discovery of Titan submersible debris en.as.com - July 19 at 9:22 AM
	Destiny 2 best Titan build for PvE and PvP videogamer.com - July 18 at 7:32 AM
	Presumed human remains found in Titan sub debris bbc.co.uk - July 14 at 5:59 PM
	The Titan submersible imploded, killing all 5 on board asahi.com - July 9 at 10:09 AM
	Debris and 'Presumed Human Remains' Recovered From Titan Submersible msn.com - June 30 at 7:39 PM
	US Coast Guard says 'presumed human remains' found in wreckage of Titan submersible wbaltv.com - June 30 at 1:27 PM
	Titan Sub Tragedy: "Presumed Human Remains" and Mangled Debris Recovered From Atlantic Ocean eonline.com - June 29 at 9:37 AM
	Possible human remains recovered from Titan wreckage, Coast Guard says msn.com - June 28 at 11:36 PM
	Titan submersible tragedy could lead to lawsuits and regulatory changes, experts say yahoo.com - June 24 at 12:27 PM
	What happens during a catastrophic implosion? Titan submersible occupants likely died instantly winknews.com - June 24 at 1:01 AM
	The science that put the Titan submersible at risk of implosion ktbs.com - June 24 at 1:01 AM
	The Titan submersible: What could have gone wrong? msn.com - June 21 at 2:23 PM
	Report: Banging sounds heard during Titan submersible search, according to internal memo wlox.com - June 21 at 12:43 AM
	Titan Medical Shares Slide as Company Pivots to IP Licensing marketwatch.com - June 20 at 2:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Atossa Therapeutics

NASDAQ:ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Obalon Therapeutics

NASDAQ:OBLN

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.

Titan Medical

NASDAQ:TMDI

Titan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial